Hironori Hayashi

Assistant Professor

Tohoku University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hironori Hayashi is an Assistant Professor at Tohoku University, Japan. His research focuses on viral replication, antibacterial compounds, and structural biology, as evidenced by his recent publications on SARS-CoV-2 inhibitors, novel antibacterial drugs, and fusion inhibitors for viruses such as measles. He utilizes advanced methodologies, including artificial intelligence, to explore peptide inhibitors and enhance drug screening systems.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (1)

Shinya Oishi

Kyoto University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hironori Hayashi

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

An orally available P1′-5-fluorinated M<SUP>pro</SUP> inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier

Binding of a potential antibacterial drug, mangiferin, to serine hydroxymethyltransferase from<i> Enterococcus</i><i> faecium</i>

Elucidation of Postfusion Structures of the Measles Virus F Protein for the Structure-Based Design of Fusion Inhibitors

Helical peptides with disordered regions for measles viruses provide new generalized insights into fusion inhibitors

Janus-Type Immunofluorescent Probes and a Quantitative Immunoassay System

Structural and virologic mechanism of the emergence of resistance to M<sup>pro</sup> inhibitors in SARS-CoV-2

SHIN-2 exerts potent activity against VanA-type vancomycin-resistant<i> Enterococcus faecium</i> in vitro by stabilizing the active site loop of serine hydroxymethyltransferase

Synthesis and Cytotoxicity of Cyclic Octapeptide Surugamides with Varied<i> N</i>-Acyl Moieties

Establishing an accurate and sensitive in vitro drug screening system for human adenovirus infection with human corneal cells

GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants

Identification of SARS-CoV-2 M-pro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602

Disseminated tuberculosis with paradoxical reactions caused by a Mycobacterium tuberculosis strain belonging to the Indo-Oceanic lineage: An imported case in Japan

Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro

Potent and biostable inhibitors of the main protease of SARS-CoV-2

Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5

Collaborators (1)

Shinya Oishi

Make your next move.